Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications

Reuters

2025/08/01

Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications

Sellas Life Sciences Group Inc. recently held a corporate presentation discussing its advancements in the field of novel therapies, specifically focusing on two clinical-stage assets with potential first and best-in-class status. The company's lead indication is acute myeloid leukemia $(AML.AU)$ for both therapies. The presentation highlighted Galinpepimut-S $(GPS.AU)$, an innovative immunotherapy targeting the Wilms Tumor 1 (WT1) antigen, currently in a Phase 3 REGAL clinical trial for AML patients achieving a second complete remission (CR2). Interim analysis demonstrated potential efficacy, with a final analysis expected in 2025. GPS has shown promising results in previous trials, with a median overall survival $(OS)$ notably higher than expected for relapsed/refractory AML patients. Additionally, the company discussed SLS009 (tambiciclib), a novel CDK9 inhibitor, which met all primary endpoints in a Phase 2 trial for relapsed/refractory AML. The presentation also covered regulatory designations received from the FDA and EMA. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556812129"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556812129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556812129?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556812129","market":"fut","top_or_hot":-1,"title":"Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sellas Life Sciences Group Inc. recently held a corporate presentation discussing its advancements in the field of novel therapies, specifically focusing on two clinical-stage assets with potential first and best-in-class status. The company's lead indication is acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> for both therapies. The presentation highlighted Galinpepimut-S <a href=\"https://laohu8.com/S/GPS.AU\">$(GPS.AU)$</a>, an innovative immunotherapy targeting the Wilms Tumor 1 (WT1) antigen, currently in a Phase 3 REGAL clinical trial for AML patients achieving a second complete remission (CR2). Interim analysis demonstrated potential efficacy, with a final analysis expected in 2025. GPS has shown promising results in previous trials, with a median overall survival <a href=\"https://laohu8.com/S/OS\">$(OS)$</a> notably higher than expected for relapsed/refractory AML patients. Additionally, the company discussed SLS009 (tambiciclib), a novel CDK9 inhibitor, which met all primary endpoints in a Phase 2 trial for relapsed/refractory AML. The presentation also covered regulatory designations received from the FDA and EMA. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-01 22:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sellas Life Sciences Group Inc. recently held a corporate presentation discussing its advancements in the field of novel therapies, specifically focusing on two clinical-stage assets with potential first and best-in-class status. The company's lead indication is acute myeloid leukemia <a href=\"https://laohu8.com/S/AML.AU\">$(AML.AU)$</a> for both therapies. The presentation highlighted Galinpepimut-S <a href=\"https://laohu8.com/S/GPS.AU\">$(GPS.AU)$</a>, an innovative immunotherapy targeting the Wilms Tumor 1 (WT1) antigen, currently in a Phase 3 REGAL clinical trial for AML patients achieving a second complete remission (CR2). Interim analysis demonstrated potential efficacy, with a final analysis expected in 2025. GPS has shown promising results in previous trials, with a median overall survival <a href=\"https://laohu8.com/S/OS\">$(OS)$</a> notably higher than expected for relapsed/refractory AML patients. Additionally, the company discussed SLS009 (tambiciclib), a novel CDK9 inhibitor, which met all primary endpoints in a Phase 2 trial for relapsed/refractory AML. The presentation also covered regulatory designations received from the FDA and EMA. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL3kQJ70:1","article_id":"2556812129","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556812129","pubTimestamp":1754060370,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLS":"SELLAS Life Sciences Group Inc."},"translate_title":"Sellas Life Sciences Group Inc.发布公司演示文稿，重点介绍AML和其他适应症新疗法的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":0.9},"content_text":"Sellas Life Sciences Group Inc. Unveils Corporate Presentation Highlighting Progress in Novel Therapies for AML and Other Indications\n    \n\n        Sellas Life Sciences Group Inc. recently held a corporate presentation discussing its advancements in the field of novel therapies, specifically focusing on two clinical-stage assets with potential first and best-in-class status. The company's lead indication is acute myeloid leukemia $(AML.AU)$ for both therapies. The presentation highlighted Galinpepimut-S $(GPS.AU)$, an innovative immunotherapy targeting the Wilms Tumor 1 (WT1) antigen, currently in a Phase 3 REGAL clinical trial for AML patients achieving a second complete remission (CR2). Interim analysis demonstrated potential efficacy, with a final analysis expected in 2025. GPS has shown promising results in previous trials, with a median overall survival $(OS)$ notably higher than expected for relapsed/refractory AML patients. Additionally, the company discussed SLS009 (tambiciclib), a novel CDK9 inhibitor, which met all primary endpoints in a Phase 2 trial for relapsed/refractory AML. The presentation also covered regulatory designations received from the FDA and EMA. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}